Roche Genome Sequencer 20 System

罗氏基因组测序仪 20 系统

• 批准号: 7213845
• 负责人: Roger E. Bumgarner
• 金额: $ 50万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7213845
• 关键词: Roche; Genome; Sequencer; 20; System

DESCRIPTION (provided by applicant): In this shared instrumentation grant, we are seeking funds to purchase a Roche Genome Sequencer 20 (GS20). This instrument is based on the revolutionary sequencing technology developed at 454 Life Sciences and now distributed through Roche Diagnostics. Described in a Nature article in Sept. 2005 [1], the GS20 provides approximately two hundred thousand, 100 base pair sequence reads in a single 4.5hr run at a cost of a little over $6,000 in reagents and supplies. That is, one can obtain 20Mbp of sequence, with 2-3 days of sample preparation at a cost that is 100 fold (on a per bp basis) lower than standard electrophoresis based technologies. This technology provides radical new opportunities for high throughput discovery which will be initially applied at the University of Washington in the following areas: 1) Sequencing of clinical isolates and phenotypically interesting strains of previously sequenced bacterial genomes. For many pathogenic bacteria, large collections of clinical isolates with varying pathogenicity exist both at the University of Washington and elsewhere. While a large number of molecular biological techniques exist that one can use to hunt for genomic regions that are correlated with phenotype, all present day methods are time consuming and tedious. Inexpensive sequencing of bacterial genomes will enable a far more efficient identification and characterization of pathogen sequence traits that correlated with clinical outcomes. 2) Characterization of sequence distributions within retroviral populations. Retroviral genomes rapidly mutate within the host in response to both the host defenses and therapy. This sequencing technology will be applied to a gaining a more rapid understanding of viral evolution that will aid in the development of vaccines and treatments. 3) Rapid re-sequencing of selected genomic regions or cDNA's in mammalian genomes. With modest modifications to currently published protocols, this technology will be adapted to high throughput, full length sequencing of pools of cDNA's and to deep re- sequencing of selected genes in a population to identify rare polymorphisms.

描述（由申请人提供）：在此共享仪器赠款中，我们正在寻求资金购买Roche Genome Sequencer 20（GS20）。该乐器基于在454个生命科学开发的革命性测序技术，现在通过Roche Diagnostics分发。在2005年9月的《自然文章》中描述的[1]中，GS20在单个4.5小时运行中提供了大约2000万，100个碱基对序列读取，其试剂和耗材的成本略高于6,000美元。也就是说，一个人可以获得20Mbp的序列，并以2-3天的样品制备，成本比基于标准电泳的技术低100倍（以每BP为基础）。这项技术为高吞吐量发现提供了根本的新机会，最初将在华盛顿大学在以下领域应用：1）临床分离株的测序以及先前测序的细菌基因组的表型有趣菌株。对于许多致病细菌，华盛顿大学和其他地方都存在着大量具有不同致病性的临床分离株。尽管存在大量的分子生物学技术，可以用来寻找与表型相关的基因组区域，但所有当今的方法都是耗时且乏味的。细菌基因组的廉价测序将使与临床结局相关的病原体序列特征的效率更有效地鉴定和表征。 2）逆转录病毒种群中序列分布的表征。逆转录病毒基因组响应宿主防御和治疗而在宿主内迅速突变。该测序技术将应用于对病毒进化的更快了解，这将有助于开发疫苗和治疗。 3）哺乳动物基因组中选定的基因组区域或cDNA的快速重新续订。通过对当前发表的方案进行适度的修改，该技术将适应高吞吐量，对cDNA的池的全长测序，并在人群中对选定基因进行深入分组，以识别罕见的多态性。